TABLE 1.
Patients and control individuals
| P | -DRB1* | -A, -B* | P | -DRB1* | -A, -B* | C | -DRB1* | -A, -B* |
|---|---|---|---|---|---|---|---|---|
| R1 | 03/04 | A2–3, B18–38 | R20 | 03/04 | A1–24, B8- | C1 | nd | A2–29, B7–44 |
| R2 | 04/13 | A2–24, B27- | R21 | 03/04 | A24–25, B18–56 | C2 | nd | A2–3, B38–51 |
| R3 | 03/11 | A2–30, B16–18 | R22 | 03/03 | A1–24, B16–39 | C3 | nd | A24–28, B7–8 |
| R4 | 03/16 | A2-, B45–18 | R23 | 04/08 | A3–24, B39–49 | C4 | nd | A1–30, B8–13 |
| R5 | 01/03 | A2-, B8- | R24 | 04/08 | A24–80, B44–51 | C5 | nd | A1–32, B8–13 |
| R6 | 03/16 | A2–11, B7–55 | R25 | 03/03 | A9–10, B8–14 | C6 | nd | A2–31, B35–60 |
| R7 | 03/04 | A2-, B62–52 | R26 | 03/04 | A1–2, B8–15 | C7 | nd | A2-, B8- |
| R8 | 03/04 | A2-, B8–44 | L1 | 03/04 | A2-, B35–62 | C8 | nd | A2–3, B7–12 |
| R9 | 03/11 | A2-, B8–51 | L2 | 03/04 | A2–29, B7–35 | C9 | nd | A2-, B27–44 |
| R10 | 04/04 | A2–3, B14–44 | L3 | 01/01 | A2–24, B7–35 | C10 | 03/04 | A1–2, B8–50 |
| R11 | 04/13 | A2–3, B15–50 | L4 | 04/04 | A2-, B39–62 | C11 | nd | A2–3, B7–50 |
| R12 | 01/04 | A2–3, B15–35 | L5 | 03/03 | A1–24, B8–45 | C12 | nd | A1–3, B8–27 |
| R13 | 03/04 | A2–24, B49- | L6 | 03/04 | A1–24, B8–49 | D1 | nd | A2–10, B12–44 |
| R14 | 07/13 | A1–2, B12–44 | L7 | 04/13 | A11–24, B50–62 | D2 | 03/15 | A2-, B35–44 |
| R15 | 03/13 | A2-, B8- | L8 | 03/04 | A1–3, B8–49 | D3 | 03/14 | A1–11, B8–55 |
| R16 | 03/04 | A2–3, B8–18 | L9 | 03/03 | A3–31, B8–51 | D4† | 03/13 | A2-, B38–45 |
| R17 | 04/16 | A1–24, B8–44 | L10 | 03/04 | A1–9, B8–21 | D5† | 01/11 | A1–2, B7- |
| R18 | 03/08 | A3–24, B8–58 | L11 | 03/04 | A1-, B8–38 | D6† | 03/07 | A1–19, B8–44 |
| R19 | 01/04 | A3–24, B35–47 | L12 | 03/04 | A1-, B8–44 |
P, patients; R, recent-onset diabetes; L, long-standing diabetes; C, healthy control subjects; D, type 2 diabetic control subjects; nd, not done.
*
HLA alleles.
†
Insulin treated.